Mizuho Securities Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Beat and Raise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Sucampo Pharmaceuticals (SCMP) PT Raised to $19 at Maxim Group
November 15, 2016 7:33 AM ESTMaxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $19.00 (from $17.00).
Kolbert highlighted:
Sucampo reported 3Q16 results with total revenues of $57.9M, up 11% sequentially, which we consider to be good sequential growth. Total revenues included product sales of $31.6M ($29.1M from AMITIZA) and royalty revenue of $20.8M from Takeda. The quarterly revenues include an additional $13.3M from the R-Tech Ueno acquisition. While AMITIZA total... MoreJefferies Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Report
November 10, 2016 10:10 AM ESTJefferies reiterated a Hold rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), and raised the price target to $16.00 (from $14.00), following the company's 3Q earnings report. SCMP reported 3Q EPS of $0.28, compared to Jefferies' $0.25 estimate. Revenues of $58M, +$7M ahead of estimates. Based on the Q3... More
